On the recordJuly 28, 2021
So if FDA had a similar authority for a conditional approval pathway, would that give the FDA more flexibility in getting potentially promising therapies to dying patients sooner?
Source
congress.govAnna Eshoo: “So if FDA had a similar authority for a conditional approval pathway, would that give the FDA more flexibility in…”
Editor's note · Context
Eshoo questions the FDA's ability to expedite drug approvals for critical patients.
Share
More from Anna Eshoo
Apr 25, 2023
The PBM Accountability Act will finally shed a light on the opaque drug pricing system.
Jun 20, 2023
Chairwoman Rosenworcel, for as long as I can remember, you have been in my view the leading voice about the need to close the digital divide and the homework gap.
Apr 18, 2023
universal high-speed internet is necessary for our country's competitiveness in the 21st century.
Other voices in this conversation
